# Merck Sharp & Dohme LLC: Phase 3 study in Bladder Cancer (400 participants)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) |
| NCT ID | NCT07829783 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Bladder Cancer |
| Intervention types | biological, drug, radiation |
| Target enrollment | 400 |
| Posted | 2026-09-21 |
| Planned start | 2026-10-20 |
| Event | Newly registered study |
| Event date | 2026-09-21 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 400 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07829783). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.